Last reviewed · How we verify
Ofatumumab combined with SB-485232
Ofatumumab combined with SB-485232 is a Small molecule drug developed by Michael John Robertson. It is currently in Phase 1 development.
At a glance
| Generic name | Ofatumumab combined with SB-485232 |
|---|---|
| Sponsor | Michael John Robertson |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ofatumumab combined with SB-485232 CI brief — competitive landscape report
- Ofatumumab combined with SB-485232 updates RSS · CI watch RSS
- Michael John Robertson portfolio CI
Frequently asked questions about Ofatumumab combined with SB-485232
What is Ofatumumab combined with SB-485232?
Ofatumumab combined with SB-485232 is a Small molecule drug developed by Michael John Robertson.
Who makes Ofatumumab combined with SB-485232?
Ofatumumab combined with SB-485232 is developed by Michael John Robertson (see full Michael John Robertson pipeline at /company/michael-john-robertson).
What development phase is Ofatumumab combined with SB-485232 in?
Ofatumumab combined with SB-485232 is in Phase 1.